Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.63 |
| ▸ | PPARA | Q07869 | 15/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 14/20 | 0.63 |
| ▸ | PTGES | O14684 | 12/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27929715 | 0.90 | CYP2C9 (0.56) | PPARGPPARAALOX5PTGESCYP2C9 | |
| SCHEMBL4427044 | 0.90 | CYP2C9 (0.56) | PPARGPPARAALOX5PTGESCYP2C9 | |
| SCHEMBL5080497 | 0.85 | PPARG (0.72) | PPARGPPARAALOX5PTGESHSD17B10 | |
| SCHEMBL1565028 | 0.84 | ALOX5 (0.53) | PPARGPPARAALOX5PTGESCYP2C9 | |
| SCHEMBL7393331 | 0.83 | HTT (0.70) | PPARGPPARAALOX5PTGESCYP2C9 | |
| SCHEMBL7345917 | 0.82 | PPARG (0.72) | PPARGPPARAALOX5PTGES | |
| SCHEMBL5081085 | 0.81 | PPARG (0.66) | PPARGPPARAALOX5PTGESHSD17B10 | |
| SCHEMBL10418815 | 0.81 | CYP2C9 (0.49) | PPARGPPARAALOX5PTGESCYP2C9 | |
| SCHEMBL11518885 | 0.80 | PTGES (0.51) | PPARGPPARAALOX5PTGES | |
| SCHEMBL9099026 | 0.79 | PPARG (0.64) | PPARGPPARAALOX5PTGESHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | disclosed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | disclosed |
| CN-1658871-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2005-08-24 | — | — | CN | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | PPARG 75/4885PPARA 303/4885ALOX5 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.